Genmab to Broaden and Strengthen Oncology Portfolio with
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in...
Source: globenewswire.com
📰 Baiteng Zhao News
Baiteng Zhao News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Baiteng Zhao. Real-time updates on events, politics, business and more.
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Company Announcement Genmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart...
Source: marketscreener.com
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
Company AnnouncementGenmab to acquire ProfoundBio for USD 1.8 billion in cash Acquisition will give Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugate (ADC) technology platforms Rina-S is a novel, next-g...
Source: pharmiweb.com
ProfoundBio secures $112m to advance ADC portfolio for cancer
ProfoundBio has secured $112m in a Series B financing round to advance its clinical-stage antibody-drug conjugate (ADC) pipeline for cancer treatment.
ProfoundBio Raises $112M in Series B Funding
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
ProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointment
SEATTLE, November 02, 2023--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced the addition of multiple industry veterans to its leadership team to support its growth.
San Diego United States Keck Graduate Institute University Of Southern California Baiteng Zhao Kevin Hambly
Source: yahoo.com
ProfoundBio Highlights Broad Antitumor Activity in Preclinical Models and Trial-in-Progress for PRO1184 at AACR 2023 Annual Meeting
/PRNewswire/ -- ProfoundBio, a clinical stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential,...
United States Zhu Chen Baiteng Zhao Prnewswire Profoundbio American Association For Cancer Research American Association
Source: prnewswire.com
ProfoundBio Receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Welcomes Naomi Hunder, M.D., as Chief Medical Officer
/PRNewswire/ -- ProfoundBio, an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics, announced that it has...
United States Baiteng Zhao Prnewswire Profoundbio Naomi Hunder Affairs At Acerta Pharma Drug Administration
Source: prnewswire.com
ProfoundBio to Highlight Programs and Technology at AACR 2022 Annual Meeting; Welcomes Zhu Chen, PhD, as Chief Scientific Officer
Press release content from PR Newswire. The AP news staff was not involved in its creation.
United States Baiteng Zhao Zhu Chen Daiichi Sankyo Prnewswire Profoundbio American Association For Cancer Research
Source: apnews.com